ArticleBMC cancer2018
Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Characteristics of Cancer-Associated Thrombosis Based on Changes in Clinically Measurable Coagulation Factors and Coagulation/Fibrinolysis Markers in Patients with Cancer: A Multicenter Cross-Sectional Study.Annals of vascular diseases · 2026Article
- The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2025Article
- Risk Assessment Models for Predicting Venous Thromboembolism in Patients with Pancreatic Cancer.Cancers · 2025Article
- Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study.Cancer medicine · 2024Article
- Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.Cancers · 2023Review
- The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.BMC cancer · 2023Article
- Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma.Journal of cancer research and clinical oncology · 2021Article
- Burden of venous thromboembolism in patients with pancreatic cancer.World journal of gastroenterology · 2021Review
- Article
- Review
- Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented.Cancers · 2020Review
- Review
- Venous Thromboembolism in Japanese Patients With Pancreatic Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the prognostic effects of venous thromboembolism (VTE)-related factors in patients with metastatic pancreatic cancer receiving palliative chemotherapy. Predictive factors for VTE were also investigated.
methodsA total of 216 patients diagnosed with metastatic pancreatic cancer who received gemcitabine-based palliative chemotherapy at our institution were retrospectively evaluated.
resultsVTE occurred in 51 (23.6%) patients during treatment and did not affect survival. However, patients who were diagnosed with VTE at the beginning of chemotherapy showed poor prognosis compared with patients diagnosed with VTE during chemotherapy: all patients (hazard ratio [HR] 1.897, p = 0.008); patients diagnosed with VTE (HR = 3.768, p = 0.001). Low serum sodium (Na) (< 135 mmol/L) and high Khorana score (≥3) were strong predictive factors of early VTE (odds ratio [OR] 5.109; 95% confidence interval [95% CI] = 1.010-25.845; p = 0.049 for Khorana score, OR 10.304; 95% CI = 1.036-102.466; p = 0.047) for hyponatremia).
conclusionsOur study demonstrated that occurrence and detection of VTE in the early period of chemotherapy was the most significant VTE-related prognostic factor in patients with metastatic pancreatic cancer receiving chemotherapy. Prediction using the Khorana score and serum Na levels would be helpful in early diagnosis of VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.